Abstract
Methods From January 2010 to October 2019, a total of 23 patients who pathologically confirmed to have AITL were retrospectively analyzed. All patients underwent whole-body 18F-FDG PET/CT scan before chemotherapy. The 18F-FDG PET/CT features, clinical data, laboratory indicators, Ki67 labeling index, and survival status were collected and analyzed. Results The median follow-up was 22 months. The expected 1-, 2-, and 3-year survival rate was 72.2%, 49.6%, and 42.5%, respectively. The median overall survival (OS) was 23 months (95% confidence interval (CI): 8.459~37.541). AITL is prone to extranodal infiltration, in addition to nodal infiltration (6 patients had nodal infiltration alone, and 17 patients had both nodal and extranodal infiltration). The SUVmax of nodal lesions were higher than that for the extranodal lesions (10.43 ± 4.45, 6.64 ± 3.51, F = 2.78, t = 4.39, P < 0.01). On multivariate survival analysis, the Eastern Cooperative Oncology Group (ECOG) and SUVmax of extranodal lesions were independent predictors of OS. Conclusion Baseline 18F-FDG PET/CT results and SUVmax of extranodal lesions showed an incremental prognostic value in addition to clinical prognostic factors.
Highlights
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma diagnosed according to the World Health Organization (WHO) criteria presented in 2001
Studies showed that 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a rapidly evolving hybrid imaging technique in evaluation of infection and cancer; it has been rarely applied for predicting outcome of AITL
Elevated lactate dehydrogenase (LDH) and C-reactive protein (CRP) levels were noted in 18 and 23 cases, respectively; the increased β2-MG level was found in 18 cases; the low level of albumin was detected in 17 cases; Ki − 67 labeling index ≥ 45% was found in 15 cases; and 8 cases had serous cavity effusion as well
Summary
Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma diagnosed according to the World Health Organization (WHO) criteria presented in 2001. Studies showed that 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) is a rapidly evolving hybrid imaging technique in evaluation of infection and cancer; it has been rarely applied for predicting outcome of AITL. The 18F-FDG PET/CT features, clinical data, laboratory indicators, Ki-67 labeling index, and survival status of 23 patients with AITL were retrospectively analyzed in the present study. Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma with rapid disease progression and poor prognosis. The aim of this study was to determine the incremental prognostic value of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in addition to clinical prognostic factors. The 18F-FDG PET/CT features, clinical data, laboratory indicators, Ki67 labeling index, and survival status were collected and analyzed. Baseline 18F-FDG PET/CT results and SUVmax of extranodal lesions showed an incremental prognostic value in addition to clinical prognostic factors
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
